Truist raised the firm’s price target on Argenx to $540 from $480 and keeps a Buy rating on the shares. Based on encouraging data, the firm is introduce Sjogren’s disease contribution to its sum-of-parts valuation of Argenx while also increasing the tech value based on the company’s “impressive showing” at a recent R&D event, which highlighted “Vision 2030” with the goals of 5 new molecules, 10 indications and 50K on treatment by 2030, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
- Argenx price target raised to $504 from $490 at H.C. Wainwright
- Zai Lab, Argenx announce China NMPA approval for efgartigimod alfa injection
- argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
- Argenx to host research and development day